DMAC earnings analysis
What we found in DMAC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
DiaMedica reported a Q2 2026 diluted loss of $0.19 per share, beating the $0.20 consensus loss estimate but deteriorating from the $0.18 loss in the prior-year quarter. Revenue, margins, free cash flow and segment data were not disclosed in the supplied filing text. Clinical progress was encouraging, with significant blood-pressure reductions in 15 preeclampsia patients and ReMEDy2 enrollment above 85% of its 200-participant interim-analysis threshold, but the company remains dependent on finite cash resources of $43.5 million expected to fund operations through 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS beat consensus
- Diluted EPS was a loss of $0.19, modestly better than the $0.20 consensus loss estimate but worse than the $0.18 loss reported in Q2 2025.
- Positive preeclampsia data
- Blood-pressure reductions were statistically significant in 15 preeclampsia patients, providing a positive clinical readout for the company’s development program.
- Stroke trial nears interim analysis
- ReMEDy2 enrollment exceeded 85% of the 200-participant interim-analysis threshold, indicating the stroke trial is approaching its planned interim analysis.
- Funding runway through 2027
- Management expects $43.5 million of cash, cash equivalents and short-term investments to fund planned studies and operations through 2027.
- Effective disclosure controls
- The company concluded that disclosure controls were effective as of June 30, 2026, and reported no material change in internal control during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Finite funding runway
- The company continues to fund clinical development without reported revenue, and management’s stated $43.5 million funding pool is expected to support operations only through 2027, increasing future financing risk.
- Clinical trial execution risk
- ReMEDy2 enrollment has surpassed 85% of its 200-participant interim-analysis threshold, but the program still faces clinical, regulatory and execution risk before producing definitive results.
- Prior 10-K risks remain
- The filing states that there were no material changes to the risk factors disclosed in the 10-K for the fiscal year ended December 31, 2025; those risks remain applicable and could materially affect results.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.19
What they said about what is next.
No formal numeric revenue or EPS guidance was provided. Management stated that cash, cash equivalents and short-term investments of $43.5 million are expected to fund planned studies and operations through 2027; R&D expenses are expected to increase moderately while G&A expenses are expected to remain relatively steady.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 6, 2026
- DiaMedica Therapeutics posted a net loss of $10 million for Q1 2026, an increase from $7.7 million in the prior year, and continues to operate without revenue generation. R&D expenses surged to $8 million as the company…
- 10-K · March 30, 2026
- DiaMedica is a clinical-stage biopharmaceutical company advancing DM199 (recombinant KLK1) in preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). The 10-K highlights positive Phase 2…
- 10-Q · August 12, 2025
- DiaMedica reported a Q2 net loss of $7.699 million (EPS -$0.18) versus a loss of $5.119 million (EPS -$0.13) in Q2 2024; operating loss widened to $8.007 million from $5.638 million a year ago. The company remains a…
- 10-K · March 17, 2025
- DiaMedica is a clinical-stage biopharmaceutical company focused on DM199 for acute ischemic stroke (AIS) and preeclampsia (PE). The company emphasizes its recombinant rhKLK1 as the first and only rhKLK1 in global…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DMAC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever